This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since 2018, employment numbers in the industry have grown by 11 percent, totalling $2.9 Sectors such as research, testing, medical labs and pharmaceuticalmanufacturing expanded greatly during the pandemic, due to high demand for COVID-19 therapeutics. To date, 747 novel compounds are in production.
Q: Since the discovery of nitrosamines in medicines in 2018, regulatory agencies and industry members around the world have taken swift action to prevent unacceptable levels of nitrosamine impurities from forming in pharmaceuticals. A: Following the discovery of nitrosamines in 2018, USP, U.S.
This is the €135 million ($165 million) REPAIR Impact Fund’s sixth call for investment proposals since it was set up in 2018, and second global call. To date, REPAIR has received over 200 investment proposals and has made nine investments in its commitment to help tackle the global AMR crisis.
2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceuticalmanufacturing. Environ Sci Technol 2018, 52, 4, 1725–1734 [link].
In addition to standards for active pharmaceutical ingredients, USP also develops standards for the inactive ingredients (excipients) and other raw materials used in drug manufacturing. In a 2019 report on drug shortages, the FDA found that 62% of drug shortages occur because of quality issues in manufacturing.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content